克唑替尼作为异体干细胞移植治疗难治性间变大细胞淋巴瘤的挽救和维持治疗。
Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma.
机构信息
From aDana-Farber Cancer Institute, Harvard Medical School and bBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; cUniversity of Rochester Medical Center, University of Rochester, Rochester, New York; and dMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
出版信息
J Natl Compr Canc Netw. 2014 Mar 1;12(3):323-6; quiz 326. doi: 10.6004/jnccn.2014.0034.
The NPM-ALK fusion protein is found in ALK(+) anaplastic large cell lymphomas harboring the t(2;5) chromosomal translocation. Patients harboring ALK translocations typically have an excellent prognosis with conventional chemotherapy and a reported 5-year survival rate of 70%. Although most patients with ALK(+) anaplastic large cell lymphoma have a good prognosis, some patients do not respond to standard therapies. In patients with refractory anaplastic large cell lymphoma who can achieve remission, allogeneic stem cell transplant is a potentially curative option. This article describes a patient with refractory ALK(+) anaplastic large cell lymphoma who experienced a complete response to the ALK inhibitor crizotinib and then underwent an allogeneic stem cell transplant followed by crizotinib maintenance therapy.
NPM-ALK 融合蛋白存在于携带 t(2;5)染色体易位的 ALK(+)间变大细胞淋巴瘤中。携带 ALK 易位的患者通常对常规化疗具有良好的预后，据报道 5 年生存率为 70%。尽管大多数 ALK(+)间变大细胞淋巴瘤患者预后良好，但有些患者对标准治疗无反应。在能够缓解的难治性间变大细胞淋巴瘤患者中，异基因造血干细胞移植是一种潜在的治愈方法。本文描述了 1 例难治性 ALK(+)间变大细胞淋巴瘤患者，该患者对 ALK 抑制剂克唑替尼治疗完全缓解，随后进行了异基因造血干细胞移植和克唑替尼维持治疗。
Zotero 插件